|
Apr 1, 2007
By:
Patrick Clinton
There are whistleblowers who bring wrongdoing to light. But there are also whistleblowers whose main complaint is "I should have won." FDA seems to suffer from a serious oversupply of the second sort.
|
|
Mar 1, 2007
By:
Patrick Clinton
There are good reasons why we shouldn't permit lifestyle drugs on the market. But as a society, we've already shown that those reasons don't mean much to us.
|
|
Feb 1, 2007
By:
Patrick Clinton
A new bill says HHS has to negotiate Medicare drug prices with pharma companies. It won't work—but that's not the biggest thing wrong with it.
|
|
Jan 1, 2007
By:
Patrick Clinton
A new GAO report sets out to explain why drug development is so expensive and what to do about it. What the report says is important, but what it leaves out is a sense of how the world of pharma actually works.
|
|
Dec 1, 2006
By:
Patrick Clinton
To one major legal scholar, drug safety regulation isn't just about meeting standards, it's about what you take away from one group of patients in order to benefit the rest.
|
|
Nov 1, 2006
By:
Patrick Clinton
The US Department of Justice thinks that "Average Wholesale Price" should mean just what the words say—no more, no less. Why? It's never meant that before.
|
|
Bureaucratic? Bayer? Not if you ask Arthur Higgins. In just over two years, the head of Bayer HealthCare has proved that pharma can be a quick and nimble business.
Nov 1, 2006
By:
Patrick Clinton
When Arthur Higgins first announced that he was about to take the reins of the healthcare group at Bayer, in 2004, colleagues were surprised.
|
|
Oct 1, 2006
By:
Patrick Clinton
The problem isn't that there's conflict between safety and efficacy or between getting a useful medicine to market and protecting the public from a dangerous one. The problem is that the conflict isn't well structured. That needs to change.
|
At Wyeth, a sweeping set of initiatives is transforming the R&D operation—and spotlighting a possible futurefor drug development.
Oct 1, 2006
By:
Patrick Clinton, George Koroneos, Online Content & News Editor
In revamping its R&D department, Wyeth "really looked for people who were not going to give us the same old, 'This is how you do pharmaceutical development, dah-dah-dah,' but who could really think of different ways of doing things."
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
